dc.contributor.author | Bujanda Fernández de Pierola, Luis | es |
dc.contributor.author | Hijona Muruamendiaraz, Elizabeth | es |
dc.contributor.author | Larzabal, Mikel | es |
dc.contributor.author | Beraza, Marta | es |
dc.contributor.author | Aldazabal, Pablo | es |
dc.contributor.author | García Urkia, Nerea | es |
dc.contributor.author | Sarasqueta, Cristina | es |
dc.contributor.author | Cosme Jiménez, Ángel | es |
dc.contributor.author | Irastorza, Belen | es |
dc.contributor.author | González, Alberto | es |
dc.contributor.author | Arenas Mirave, Juan Ignacio | es |
dc.date.accessioned | 2010-12-14T11:28:26Z | es |
dc.date.accessioned | 2011-03-29T04:50:42Z | |
dc.date.available | 2010-12-14T11:28:26Z | es |
dc.date.available | 2011-03-29T04:50:42Z | |
dc.date.issued | 2008-09-09 | es |
dc.identifier.citation | BMC Gastroenterology 8(40) : (2008) | es |
dc.identifier.issn | 1471-230X | es |
dc.identifier.uri | http://hdl.handle.net/10810/2186 | es |
dc.description | Es reproducción del documenteo publicado en http://dx.doi.org/10.1186/1471-230X-8-40 | es |
dc.description.abstract | Background: The prevalence of nonalcoholic fatty liver disease (NAFLD) is high. NAFLD is linked to obesity, diabetes mellitus, and hypertriglyceridemia. Approximately 20% of patients with NAFLD will eventually develop cirrhosis. Our purpose was to investigate whether resveratrol decreased hepatic steatosis in an animal model of steatosis, and whether this therapeutic approach resulted in a decrease in tumor necrosis factor alpha (TNF-alpha) production, lipid peroxidation and oxidative stress.
Methods: Male Wistar CRL: Wi (Han) (225 g) rats were randomized into three groups. A control group (n = 12) was given free access to regular dry rat chow for 4 weeks. The steatosis (n = 12) and resveratrol (n = 12) groups were given free access to feed (a high carbohydrate-fat free modified diet) and water 4 days per week, and fasted for the remaining 3 days for 4 weeks. Rats in the resveratrol group were given resveratrol 10 mg daily by the oral route. All rats were killed at 4 weeks and assessed for fatty infiltration and bacterial translocation. Levels of TNF-alpha in serum, hepatic malondialdehyde (MDA), oxidative stress (superoxide dismutase, glutathione peroxidase, catalase and nitric oxide synthase) and biochemical parameters were measured.
Results: Fat deposition was decreased in the resveratrol group as compared to the steatosis group (Grade 1 vs Grade 3, P < 0.05). TNF-alpha and MDA levels were significantly increased in the steatosis group (TNF-alpha; 33.4 +/- 5.2 vs 26.24 +/- 3.47 pg/ml and MDA; 9.08 +/- 0.8 vs 3.17 +/- 1.45 mu M respectively, P < 0.05). This was accompanied by increased superoxide dismutase, glutathione peroxidase and catalase and decreased nitric oxide synthase in the liver of resveratrol group significantly (P < 0.05 vs steatosis group). Bacterial translocation was not found in any of the groups. Glucose levels were decreased in the group of rats given resveratrol (P < 0.05).
Conclusion: Resveratrol decreased NAFLD severity in rats. This effect was mediated, at least in part, by TNF-alpha inhibition and antioxidant activities. | es |
dc.language.iso | eng | es |
dc.publisher | BioMed Central | es |
dc.rights | info:eu-repo/semantics/openAccess | es |
dc.subject | insulin resistance model | es |
dc.subject | hepatic steatosis | es |
dc.subject | oxidative stress | es |
dc.subject | steatohepatitis | es |
dc.title | Resveratrol inhibits nonalcoholic fatty liver disease in rats | es |
dc.type | info:eu-repo/semantics/article | es |
dc.rights.holder | (c) 2008 Bujanda et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http://creativecommons.org/licenses/by/2.0),which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. | es |
dc.departamentoes | Medicina | es_ES |
dc.departamentoeu | Medikuntza | es_ES |
dc.subject.categoria | GASTROENTEROLOGY AND HEPATOLOGY | |